Travere Therapeutics (TVTX) Operating Margin: 2013-2025
Historic Operating Margin for Travere Therapeutics (TVTX) over the last 12 years, with Sep 2025 value amounting to 15.12%.
- Travere Therapeutics' Operating Margin rose 10439.00% to 15.12% in Q3 2025 from the same period last year, while for Sep 2025 it was -20.91%, marking a year-over-year increase of 15472.00%. This contributed to the annual value of -138.88% for FY2024, which is 12837.00% up from last year.
- Per Travere Therapeutics' latest filing, its Operating Margin stood at 15.12% for Q3 2025, which was up 236.82% from -11.05% recorded in Q2 2025.
- In the past 5 years, Travere Therapeutics' Operating Margin registered a high of 15.12% during Q3 2025, and its lowest value of -707.08% during Q4 2021.
- In the last 3 years, Travere Therapeutics' Operating Margin had a median value of -125.11% in 2024 and averaged -161.55%.
- In the last 5 years, Travere Therapeutics' Operating Margin tumbled by 47,455bps in 2021 and then spiked by 41,157bps in 2022.
- Quarterly analysis of 5 years shows Travere Therapeutics' Operating Margin stood at -707.08% in 2021, then surged by 41,157bps to -295.52% in 2022, then surged by 8,639bps to -209.13% in 2023, then skyrocketed by 12,792bps to -81.21% in 2024, then soared by 10,439bps to 15.12% in 2025.
- Its last three reported values are 15.12% in Q3 2025, -11.05% for Q2 2025, and -52.21% during Q1 2025.